Detection of histological type and genetic mutation in lung cancer using ion mobility spectrometry

Detection of histological type and genetic mutation in lung cancer using ion mobility spectrometry - Diagnosis of lung cancer using IMS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008328

Enrollment

Registered

2012-07-03

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To investigate if IMS can diagnosis histological type and genetic mutation using volatile organic compounds (VOCs) in patients with lung cancer.

Interventions

Lung cancer: To collect 10ml of exhaled air using BioScout.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) No treatment of lung cancer 2) To agree to give informed consent

Exclusion criteria

Exclusion criteria: 1) To refuse to give informed consent 2) Lung cancer of unknown histological type 3) Patients with no diagnosis of lung cancer 4) Patients who are pregnant, possibly pregnant, or lactating. 5) Patients with renal failure. (serum creatinine > 2.0 mg/dL, BUN > 30mg/dl) 6) AST or ALT > 100IU 7) Patients with severe diabetes, hyperlipidemia or hyperuricemia 8) Patients who are judged inappropriate by the doctor in charge.

Design outcomes

Primary

Measure	Time frame
To investigate if IMS can diagnosis histological type and genetic mutation using volatile organic compounds (VOCs) in patients with lung cancer.	—

Countries

Japan

Contacts

Public ContactHiroshi Handa

St. Marianna University School of Medicine Division of Respiratory and Infectious Diseases, Department of Internal Medicine

044-977-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026